{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-104054","form_type":"8-K","ticker":"OM","cik":"0001484612","company_name":"Outset Medical, Inc.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.088514+00:00","generated_at":"2026-05-17T19:10:32.184896+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Outset Medical Q2 revenue up 15% to $31.4M; raises FY2025 guidance to $122-126M","bullets":["Net revenue $31.4M (+15% YoY); Tablo console revenue up 25%; recurring revenue $22.5M (+11%).","Non-GAAP gross margin 38.4% (+110bps); operating expenses down 29% YoY; net loss $18.5M vs $34.5M.","Raised 2025 revenue guidance to $122-126M from $115-125M; expects <$50M cash use vs >$100M in 2024.","New enterprise agreement with large national health system; Tablo now in >900 U.S. acute/sub-acute sites.","Cash $187.4M at June 30; H1 cash burn reduced ~60% vs prior year."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-104054","json":"https://secwatch.observer/filing/0000950170-25-104054.json","markdown":"https://secwatch.observer/filing/0000950170-25-104054.md","text":"https://secwatch.observer/filing/0000950170-25-104054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1484612/000095017025104054/0000950170-25-104054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1484612/000095017025104054/om-20250806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T19:10:32.184896+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}